Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 11

Results For "Post"

1357 News Found

IOL Chemicals and Pharmaceuticals posts Q2 FY25 PT at Rs. 19 Cr
News | November 16, 2024

IOL Chemicals and Pharmaceuticals posts Q2 FY25 PT at Rs. 19 Cr

Total Income in Q2 FY25 stood at Rs. 532.18 crore


AstraZeneca Pharma India posts Q2 PAT at Rs. 38.43 Cr
News | November 14, 2024

AstraZeneca Pharma India posts Q2 PAT at Rs. 38.43 Cr

We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%


Akums Drugs and Pharmaceuticals posts Q2 FY25 adjusted PAT at Rs. 66.7 Cr
News | November 11, 2024

Akums Drugs and Pharmaceuticals posts Q2 FY25 adjusted PAT at Rs. 66.7 Cr

For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore


Emcure Pharmaceuticals posts Q2 FY25 consolidated PAT at Rs. 194.57 Cr
News | November 08, 2024

Emcure Pharmaceuticals posts Q2 FY25 consolidated PAT at Rs. 194.57 Cr

Emcure Pharmaceuticals has reported total income of Rs. 2,037.63 crores during the period ended September 30, 2024


JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr
News | November 07, 2024

JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr

JB’s domestic business continued to out-perform the market with all our major brands posting strong growth


Max Healthcare posts Q2 FY25 consolidated PAT at Rs. 281.81 Cr
News | November 07, 2024

Max Healthcare posts Q2 FY25 consolidated PAT at Rs. 281.81 Cr

Max Healthcare Institute has reported total income of Rs. 1,748.30 crores during the period ended September 30, 2024


Vijaya Diagnostic Centre posts Q2 FY25 PAT at Rs. 41.95 Cr
News | November 07, 2024

Vijaya Diagnostic Centre posts Q2 FY25 PAT at Rs. 41.95 Cr

Revenue growth was fueled by higher volumes and contributions from both existing and new centres


RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY
News | November 07, 2024

RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY

Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25


Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr
News | November 06, 2024

Mankind Pharma posts Q2 FY25 PAT up 30% at Rs. 659 Cr

Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.


Dr. Reddy's Laboratories posts Q2 FY25 PAT at Rs. 1,255.3 Cr
News | November 06, 2024

Dr. Reddy's Laboratories posts Q2 FY25 PAT at Rs. 1,255.3 Cr

Dr. Reddy's Laboratories has reported total income of Rs. 8,016.2 crores during the period ended September 30, 2024